文献速递前列腺癌

雄激素受体突变调节11-氧合雄激素和糖皮质激素的激活作用

Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-01-19

该研究通过Meta分析纳入21项研究共1614例去势抵抗性前列腺癌(CRPC)患者,识别出ARL702H(3.4%)、ARH875Y(4.9%)和ART878A(4.4%)为最常见的AR配体结合域突变,并采用荧光素酶报告基因和定量荧光显微镜筛查这些突变体对内源性和外源性类固醇的敏感性。结果显示睾酮和11-酮睾酮均有效激活野生型AR,ARH875Y突变选择性增强对11-酮睾酮的敏感性,而ARL702H降低对11-酮睾酮的敏感性近50倍;地塞米松不刺激ARL702H,作者认为其可能作为泼尼松龙的合适替代并应在携带ARL702H的患者中探索。

要点

  • Meta分析显示CRPC患者中最常见AR配体结合域突变为ARL702H(3.4%)、ARH875Y(4.9%)和ART878A(4.4%)。
  • ARH875Y突变选择性增强对11-酮睾酮的敏感性(EC50:0.15 nmol/L,p < 0.05 vs 野生型AR)。
  • ARL702H降低对11-酮睾酮的敏感性近50倍;地塞米松不刺激ARL702H。

核心结论

  • 睾酮和11-酮睾酮均有效激活野生型AR,而选择性增敏使11-酮睾酮成为ARH875Y更突出的激活剂。
  • 地塞米松可能作为泼尼松龙的合适替代,并应在携带ARL702H的患者中探索。

研究设计与样本

  • 对报告AR突变无靶向分析的研究进行Meta分析,以识别临床相关的AR配体结合域突变。
  • 采用荧光素酶报告基因和定量荧光显微镜筛查这些AR突变体对各种内源性类固醇和治疗CRPC所用合成糖皮质激素的敏感性。
  • Meta分析纳入来自21项独特研究的1614例CRPC患者。

主要发现

  • ARL702H(3.4%)、ARH875Y(4.9%)和ART878A(4.4%)是1614例CRPC患者中最常见的AR配体结合域突变。
  • 睾酮(EC50:0.22 nmol/L)和11-酮睾酮(11KT,EC50:0.74 nmol/L)对野生型AR显示亚纳摩尔亲和力。
  • p.H875Y突变选择性增强AR对11KT的敏感性(EC50:0.15 nmol/L,p < 0.05 vs 野生型AR)。
  • p.L702H使对11KT的敏感性降低近50倍。
  • 皮质醇和泼尼松龙均刺激ARL702H,而地塞米松不刺激ARL702H。

关键数值与推荐

  • ARL702H在1614例CRPC患者中的患病率为3.4%。
  • ARH875Y在1614例CRPC患者中的患病率为4.9%。
  • ART878A在1614例CRPC患者中的患病率为4.4%。
  • 睾酮对野生型AR的EC50为0.22 nmol/L。
  • 11KT对野生型AR的EC50为0.74 nmol/L;对ARH875Y的EC50为0.15 nmol/L(p < 0.05 vs 野生型AR)。

临床怎么用

  • 作者认为地塞米松可能作为泼尼松龙的合适替代,并应在携带ARL702H的患者中探索。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen receptor (AR) ligand-binding domain (LBD) mutations occur in ~20% of all castration-resistant prostate cancer (CRPC) patients. These mutations confer ligand promiscuity, but the affinity for many steroid hormone pathway intermediates is unknown. In this study, we investigated the stimulation of clinically relevant AR-LBD mutants by endogenous and exogenous steroid hormones present in CRPC patients to unravel their potential contribution to AR pathway reactivation. METHODS: A meta-analysis of studies reporting untargeted analysis of AR mutants was performed to identify clinically relevant AR-LBD mutations. Using luciferase reporter and quantitative fluorescent microscopy, these AR mutants were screened for sensitivity for various endogenous steroids and synthetic glucocorticoids used in the treatment of CRPC. RESULTS: The meta-analysis revealed that ARL702H (3.4%), ARH875Y (4.9%), and ART878A (4.4%) were the most prevalent AR-LBD mutations across 1614 CRPC patients from 21 unique studies. Testosterone (EC50: 0.22 nmol/L) and 11-ketotestosterone (11KT, EC50: 0.74 nmol/L) displayed subnanomolar affinity for ARWT. The p.H875Y mutation selectively increased sensitivity of the AR for 11KT (EC50: 0.15 nmol/L, p < 0.05 vs ARWT), whereas p.L702H decreased sensitivity for 11KT by almost 50-fold. While cortisol and prednisolone both stimulate ARL702H, dexamethasone importantly does not. CONCLUSION: Both testosterone and 11KT effectively contribute to ARWT activation, while selective sensitization positions 11KT as a more prominent activator of ARH875Y. Dexamethasone may be a suitable alternative to prednisolone and should be explored in patients bearing the ARL702H.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Snaterse G, Mies R, van Weerden WM, et al. Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids. Prostate Cancer Prostatic Dis. 2022. PMID: 35046557. doi:10.1038/s41391-022-00491-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。